ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESI....FIRO..CY..TRBGCZEEHU..SK....................................*JDIM360 Ver 2.15 (14 Jul 2008) - 2999001/01585966CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120120307W173deBibliographieenBibliographyfrBibliographieEP03755724.6200307112005020420070718enenen396290 P20020715US480043 P20030620US2012030720121020051019200542201111302011482011051720120307201210A61K 39/395 20060101AFI20060110BHEP deBehandlung von Krebs mit dem anti-ErbB2-Antikörper rhuMAb 2C4enTreatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4frTraitment de cancer par l'anticorps rhuMAb 2C4WO-A-01/00245WO-A-01/09186WO-A-01/89566US-A- 5 811 098US-A- 5 811 098US-A1- 2002 064 805US-B1- 6 417 168US-B1- 6 417 168XIA W ET AL: "Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. DEC 1999, vol. 5, no. 12, December 1999 (1999-12), pages 4164-4174, XP002400085 ISSN: 1078-0432GILBERTSON RICHARD J ET AL: "Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma" CANCER RESEARCH, vol. 57, no. 15, 1997, pages 3272-3280, XP008069241 ISSN: 0008-5472LANE HEIDI A ET AL: "ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: Receptor overexpression does not determine growth dependency" MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 9, May 2000 (2000-05), pages 3210-3223, XP002400087 ISSN: 0270-7306LYNE J C ET AL: "Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro." THE CANCER JOURNAL FROM SCIENTIFIC AMERICAN. 1997 JAN-FEB, vol. 3, no. 1, January 1997 (1997-01), pages 21-30, XP002400088 ISSN: 1081-4442OLAYIOYE M: "The Erbbeta Signaling Network: Receptor Heterodimerization in Development and Cancer" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 13, January 2000 (2000-01), pages 3159-3167, XP002985171 ISSN: 0261-4189MOTOYAMA ANDREA B ET AL: "The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides" CANCER RESEARCH, vol. 62, no. 11, 11 June 2002 (2002-06-11), pages 3151-3158, XP001155498 ISSN: 0008-5472CHEN XINMEI ET AL: "Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 277, no. 3, 2 November 2000 (2000-11-02), pages 757-763, XP002400090 ISSN: 0006-291XBROCKHOFF GERO ET AL: "Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells" CYTOMETRY, vol. 44, no. 4, 1 August 2001 (2001-08-01), pages 338-348, XP002400091 ISSN: 0196-4763NEVE RICHARD M ET AL: "Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells" ONCOGENE, vol. 19, no. 13, 23 March 2000 (2000-03-23), pages 1647-1656, XP002400092 ISSN: 0950-9232AGUS D.B. ET AL: 'Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth' CANCER CELL vol. 2, August 2002, pages 127 - 137, XP002988666TZAHAR E. ET AL: 'The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands' BIOCHEMICA ET BIOPHYSICA ACTA vol. 1377, 20 February 1998, pages M29 - M34, XP004281795SLIKOWSKI M.X. ET AL: 'Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 269, no. 20, 20 May 1994, pages 14661 - 14665, XP000605388QIAN X. ET AL: 'p185c-neu and Epidermal Growth Factor Receptor Associated into Structure Composed of Activated Kinases' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol. 89, February 1992, pages 1330 - 1334, XP002988667GORDON MICHAEL S ET AL: "Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 24, no. 26, 10 September 2006 (2006-09-10), pages 4324-4332, XP002492090, ISSN: 0732-183X, DOI: DOI:10.1200/JCO.2005.05.4221 [retrieved on 2006-08-07]BASELGA, J. ET AL.: "Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which as progressed during treatment with T", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18S, 20 June 2007 (2007-06-20), page 1004,MAKHIJA, S. ET AL.: "Results from a phase II randomzied, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18S, 20 June 2007 (2007-06-20), page 5507,CHEE M NG ET AL: "Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 23, no. 6, 26 May 2006 (2006-05-26), pages 1275-1284, XP019405128, ISSN: 1573-904X, DOI: DOI:10.1007/S11095-006-0205-XALLISON, D. ET AL,: "Pharmacokinetics (PK) of Pertuzumab (rhuMAb 2C4) in Phase II Studies of Ovarian, Breast, Prostate, and Lung Cancers", , 2005, page 2532,2007012210176072.6226369120100909KOLL, HansBlütenanger 4585247 OberrothDEBOSSENMAIER, BirgitHorst-Wolfram-Geissler-Weg 1082229 SeefeldDEMÜLLER, Hans-JoachimRuhe am Bach 5 b82377 PenzbergDESLIWKOWSKI, Mark, X.42 Oak Creek LaneSan Carlos, CA 94070USKELSEY, Stephen, Michael360 14th StreetMontara, CA 94037USF.Hoffmann-La Roche AG100120526SMW/FP6271563Grenzacherstrasse 1244070 BaselCHWalton, Seán Malcolmet al100036945Mewburn Ellis LLP 33 Gutter LaneLondon EC2V 8ASGBATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEITLILUMCNLPTROSESISKTRUS200302159020030711enWO200400809920040122200404